<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00790296</url>
  </required_header>
  <id_info>
    <org_study_id>05-269-2</org_study_id>
    <secondary_id>601</secondary_id>
    <nct_id>NCT00790296</nct_id>
  </id_info>
  <brief_title>Evaluation of Synthetic Thyrotropin Releasing Hormone (TRH) as a Treatment for Cancer-related Fatigue</brief_title>
  <official_title>A Pilot, Randomized Double-Blind Placebo-Controlled Crossover Study of Synthetic Thyrotropin Releasing Hormone (TRH) Administration for the Treatment of Fatigue in Patients With Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UConn Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Susan G. Komen Breast Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hollfelder foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UConn Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate thyrotropin releasing hormone (TRH) as a
      treatment for cancer-related fatigue.

      The central hypothesis of this pilot study is that TRH is more efficacious than placebo in
      alleviating cancer-related fatigue in patients with breast or prostate cancer.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim analyses showed statistically and clinically significant results.
  </why_stopped>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Visual Analog Scale for Energy (VAS-E)Score From Baseline to 7 Hrs Post Study Medication Infusion</measure>
    <time_frame>Baseline and 7 hours post study medication infusion</time_frame>
    <description>1 to 100 scale with 1 referring to No Energy and 100 referring to Normal Energy.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Cancer-related Fatigue</condition>
  <arm_group>
    <arm_group_label>Thyrotropin releasing hormone (TRH)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TRH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thyrotropin releasing hormone (TRH)</intervention_name>
    <description>0.5mg and 1.5mg</description>
    <arm_group_label>Thyrotropin releasing hormone (TRH)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of cancer who have undergone or are currently undergoing
             radiation or chemotherapy therapy and are expected not to have any significant change
             in cancer treatment sessions during the study period

          -  Provide written informed consent prior to initiation of any study-related procedures.

          -  Male or female, 18 years of age or older with a diagnosis of cancer.

          -  Able to understand and comply with the requirements of the study.

        Exclusion criteria:

          -  Hospitalized patients.

          -  Patients with an identifiable diagnosis of substance abuse or dependence within 6
             months prior to evaluation (except those in full remission, or those with caffeine or
             nicotine dependence) as defined by DSM-IV criteria.

          -  Patients with any of the following cardiovascular symptomatology.

          -  Office systolic BP &gt; 160mmHg and/or diastolic BP &gt; 90mmHg.

          -  Persons with a resting hear rate of &gt; 100 beats per minute

          -  Persons with a history of chronic stable angina

          -  Persons with myocardial infarction or unstable angina or vascular surgery within 6
             months

          -  Persons with history of vaso-vagal or other syncopal episodes

          -  Patients with any known clinically significant cardiac problems

          -  Patients with any history of stroke or at significant risk for stroke.

          -  Patients with a history of seizures

          -  Patients with a history of asthma

          -  Patients with any clinically significant unstable or inadequately treated co- morbid
             medical condition or patients currently on medications that would confound evaluation
             of CF (e.g. diabetes, CHF, history of other cancers) as judged by the investigator.

          -  Patients with any clinically significant, unstable psychiatric disorder (except mild
             to moderate depressive or anxiety disorders) or patients on psychotropic medications
             that would confound CF assessment as judged by the investigator. Patients with history
             of depressive or anxiety disorders will not be excluded from the study

          -  Patients with a history of illnesses or treatments that would be expected to
             significantly alter immune function (viz. HIV infection, systemic lupus erythematosus,
             patients taking immunosuppressive medications).

          -  Patients with diseases or on medications that significantly affect the
             hypothalamic-pituitary-adrenocortical (HPA) axis function (viz. Cushings disease).

          -  Pregnant patients, breastfeeding or plans to become pregnant during the study

          -  Patients with known allergy to TRH

          -  Any other condition, which, in the opinion of the investigator, would make the
             patient, unsuited for enrollment, confound CF evaluation or could interfere with the
             patient's participation in the study.

          -  Patients with medically reversible causes of CF (viz., anemia, hypothyroidism,
             electrolyte abnormalities etc).

          -  Patients with potentially treatable associated symptoms dominating the CF scenario
             such as pain, or sleep disturbances which may have a significant causal relationship
             to CF.

          -  Patients identified as pregnant based on the pregnancy test during screening.

          -  Patients physically unable to complete the walking test (WT) assessment or when the WT
             would increase risk for medical complications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Winokur, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UConn Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2008</study_first_submitted>
  <study_first_submitted_qc>November 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2008</study_first_posted>
  <results_first_submitted>January 31, 2011</results_first_submitted>
  <results_first_submitted_qc>April 5, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 3, 2011</results_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer fatigue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Thyrotropin-Releasing Hormone</mesh_term>
    <mesh_term>Calcitonin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited per referrals from oncology clinics at UCHC and Gray Cancer Center at Hartford Hospital</recruitment_details>
      <pre_assignment_details>Two participants signed informed consent but was not randomized as she did not meet study eligibility criteria</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TRH Then Saline</title>
          <description>TRH (0.5mg) given first followed by Saline</description>
        </group>
        <group group_id="P2">
          <title>Saline Then TRH</title>
          <description>Saline given first followed by TRH (0.5 mg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not meet study eligibility criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TRH Then Saline</title>
          <description>TRH (0.5mg) given first followed by Saline</description>
        </group>
        <group group_id="B2">
          <title>Saline Then TRH</title>
          <description>Saline given first followed by TRH (0.5 mg)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="9.4"/>
                    <measurement group_id="B2" value="58" spread="9.4"/>
                    <measurement group_id="B3" value="58" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Visual Analog Scale for Energy (VAS-E)Score From Baseline to 7 Hrs Post Study Medication Infusion</title>
        <description>1 to 100 scale with 1 referring to No Energy and 100 referring to Normal Energy.</description>
        <time_frame>Baseline and 7 hours post study medication infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thyrotropin-releasing Hormone (TRH)</title>
            <description>TRH given as 0.5mg and 1.5mg intravenously</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Saline given Intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Analog Scale for Energy (VAS-E)Score From Baseline to 7 Hrs Post Study Medication Infusion</title>
          <description>1 to 100 scale with 1 referring to No Energy and 100 referring to Normal Energy.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.67" spread="21.1"/>
                    <measurement group_id="O2" value="-1.67" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Thyrotropin-releasing Hormone (TRH)</title>
          <description>TRH given as 0.5mg and 1.5mg intravenously</description>
        </group>
        <group group_id="E2">
          <title>Saline</title>
          <description>Saline given intravenously</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitation: small sample size</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Andrew Winokur MD PhD</name_or_title>
      <organization>University of Connecticut Health Center</organization>
      <phone>860-679-6775</phone>
      <email>awinokur@uchc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

